Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study

Naomi Gronich; Idit Lavi; Gad Rennert

doi:10.1503/cmaj.110463

Submit a Response to This Article

Compose Response

Title *

References

Author Information

Contributors

First Name and Middle Initial *

First or given name, e.g. 'Peter'.

Last Name *

Your last, or family, name, e.g. 'MacMoody'.

Degrees

Email Address *

Your email address, e.g. higgs-boson@gmail.com

Occupation *

Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.

Affiliation *

Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.

Address

Your organization, institution's or residential address.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

Drospirenone and venous thromboembolism; Do prescribing practices impose bias?
Steven T Bird

Posted on: 20 December 2011
Drospirenone may Increase Thrombosis by Decreasing DHEA
James M. Howard

Posted on: 14 December 2011

Posted on: (20 December 2011)

Drospirenone and venous thromboembolism; Do prescribing practices impose bias?
Steven T Bird, Pharmacist
Your recent article on drospirenone and venous thromboembolism (VTE) highlighted vast differences between drospirenone and second-generation oral contraceptives (OC) users for smoking [26.28 % versus 18.48%] and obesity [13.41% versus 26.44%] [1]. These differences were not observed in the European Active Surveillance Study which interviewed patients at baseline [2], or the INGENIX study [3], which sampled 10% of patien...
Show More

Your recent article on drospirenone and venous thromboembolism (VTE) highlighted vast differences between drospirenone and second-generation oral contraceptives (OC) users for smoking [26.28 % versus 18.48%] and obesity [13.41% versus 26.44%] [1]. These differences were not observed in the European Active Surveillance Study which interviewed patients at baseline [2], or the INGENIX study [3], which sampled 10% of patients to assess for these covariates. Do you think this reflects differences in prescribing practices between Israel and either Germany or the United States? Might these differences suggest the presence of other potential unmeasured confounders?
The selective prescribing of drospirenone in patients with polycystic ovary syndrome (PCOS), discussed at the December 8th FDA advisory committee meeting, raised concern for confounding by indication. We recently acquired an OC cohort in IMS data to evaluate gall bladder disease with use of drospirenone [4]. In further evaluation, we found that 6.05% of women taking drospirenone/ethinyl-estradiol 0.03mg had PCOS, compared to 2.09% of women taking levonorgestrel/ethinyl-estradiol 0.03mg. (unpublished: 2011) Because women with PCOS are known to represent a population at high risk for VTE, this could be a potential issue for previous studies. Do you have data on the prevalence of polycystic ovary syndrome (PCOS) in your study population?
I would appreciate any comments you provide.
References
1. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population- based cohort study. [published online ahead of print November 7, 2011]. CMAJ. 2011:doi:10.1503/cmaj.110463.
2. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344-354.
3. Eng PM, Seeger JD, Loughlin J, et al. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. Pharmacoepidemiol Drug Saf. 2008;17:297 -305.
4. Etminan M, Delaney JA, Bressler B, et al. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ 2011;183(8):899-904.
Conflict of Interest:
This letter represents the opinion of the author and not those of the Food and Drug Administration.
Show Less

Competing Interests: None declared.
Posted on: (14 December 2011)

Drospirenone may Increase Thrombosis by Decreasing DHEA
James M. Howard, Biologist
Other Contributors:
It is my hypothesis that low DHEA may be the cause of venous thrombosis. Low DHEA may be connected with many major symptoms resulting in thrombosis. "Thrombosis May Be Caused by Low DHEA" http://anthropogeny.com/Thrombosis%20May%20Be%20Caused%20by%20Low%20DHEA.htm .
Drospirenone has been demonstrated to reduce DHEAS, the precursor of DHEA, by 20-50% (Contraception 2011; 82: 276-80).
Since the mechan...
Show More

It is my hypothesis that low DHEA may be the cause of venous thrombosis. Low DHEA may be connected with many major symptoms resulting in thrombosis. "Thrombosis May Be Caused by Low DHEA" http://anthropogeny.com/Thrombosis%20May%20Be%20Caused%20by%20Low%20DHEA.htm .
Drospirenone has been demonstrated to reduce DHEAS, the precursor of DHEA, by 20-50% (Contraception 2011; 82: 276-80).
Since the mechanism whereby oral contraceptives exert their effects may be by reducing DHEA, drospirenone may be a very effective oral contraceptive. However, the fact that drospirenone may decrease DHEA beyond certain levels in certain individuals may account for the increase in thrombosis caused by drospirenone
Conflict of Interest:
None declared
Show Less

Competing Interests: None declared.